| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCK |
| Uniprot No | P06239 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-539aa |
| 氨基酸序列 | MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPLQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANSLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHYKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVPRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLVRLYAVVTQEPIYIITEYMENDTLLDSQLEEKGLGASPWGNLGQQLLLLPTGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYIHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKSDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERPEDRPTFDYLRSVLEDFFTATEGQYQPQP |
| 预测分子量 | 65.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LCK重组蛋白的虚构参考文献示例(仅供参考，非真实文献)：
---
1. **文献名称**：*Expression and Purification of Recombinant LCK Tyrosine Kinase for Structural Studies*
**作者**：Kim J. et al.
**摘要**：研究通过大肠杆菌表达系统成功表达并纯化重组LCK激酶结构域，利用X射线晶体学解析其三维结构，为靶向T细胞信号通路的药物设计提供基础。
2. **文献名称**：*Functional Characterization of LCK Mutants in Autoimmune Disease Models*
**作者**：Smith R.L. & Patel T.
**摘要**：通过重组LCK蛋白构建多种突变体，分析其在T细胞活化中的功能差异，发现特定突变与自身免疫性疾病中异常信号传导的相关性。
3. **文献名称**：*Development of LCK Inhibitors Using Recombinant Protein-Based Screening*
**作者**：Wang H. et al.
**摘要**：基于重组LCK蛋白的高通量筛选平台，鉴定出两种新型小分子抑制剂，实验显示其可有效抑制T细胞增殖，具有潜在治疗炎症性疾病的疗效。
4. **文献名称**：*Optimizing LCK Recombinant Production in Mammalian Cell Systems*
**作者**：Gomez M. et al.
**摘要**：比较哺乳动物细胞(HEK293)与昆虫细胞表达系统对重组LCK蛋白活性的影响，发现哺乳动物系统表达的蛋白具有更接近天然构象的磷酸化修饰。
---
注：以上文献为示例性内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
**Background of LCK Recombinant Protein**
The lymphocyte-specific protein tyrosine kinase (LCK) is a crucial member of the Src family of kinases, primarily expressed in T-cells and natural killer (NK) cells. It plays a pivotal role in T-cell receptor (TCR) signaling, mediating early activation events by phosphorylating downstream targets such as ZAP-70. PI3K, and MAPK pathways. LCK is structurally characterized by its Src homology 3 (SH3) and SH2 domains, a catalytic tyrosine kinase domain, and a unique N-terminal region that facilitates its interaction with CD4 or CD8 co-receptors.
Recombinant LCK proteins are engineered through genetic modification, often expressed in systems like *E. coli* or mammalian cells, to ensure proper post-translational modifications. These proteins retain functional kinase activity and are widely used in biochemical assays, drug discovery, and immunological research to study TCR signaling dysregulation linked to autoimmune diseases, immunodeficiencies, and cancers.
LCK’s role in T-cell activation makes it a therapeutic target. Inhibitors of LCK are explored for modulating aberrant immune responses in conditions like rheumatoid arthritis or leukemia. Recombinant LCK variants, including mutants with altered catalytic activity (e.g., constitutively active or kinase-dead forms), enable mechanistic studies of phosphorylation-dependent signaling cascades.
The development of LCK recombinant proteins has advanced understanding of immune cell regulation, offering tools for high-throughput screening of kinase inhibitors and personalized immunotherapies. Its study continues to bridge gaps in immunology and oncology, highlighting its dual significance in basic research and clinical applications.
×
